Last reviewed · How we verify
NCT05695118
Body Composition and Fatty Liver Disease
NA trial testing Non-contrast low-dose abdomen CT in Fatty Liver in 150 participants. Status unknown.
31 December 2023
Quick facts
| Lead sponsor | Seoul National University Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 150 |
| Start date | 10 February 2023 |
| Primary completion | 31 December 2023 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Non-contrast low-dose abdomen CT
- Fibroscan
- bioelectrical impedance analysis (BIA)
Conditions studied
- Fatty Liver — all drugs for Fatty Liver →
Sponsor
Seoul National University Hospital
Who can join
20 and older, any sex, with Fatty Liver. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study investigates relationship between fatty liver prognosis and body composition analysis result based on non-contrast low dose CT in patients with fatty liver disease.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05695118
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Fatty Liver
Currently open trials in the same condition.
- NCT07242222 — Erdosteine in the Treatment of Nonalcoholic Fatty Liver Disease · Phase 1, PHASE2 · recruiting
- NCT07238985 — Cilostazol in the Treatment of Nonalcoholic Fatty Liver Disease · Phase 1, PHASE2 · recruiting
- NCT06661655 — Evaluation of a New Ultrasound System for the Non-invasive Assessment of Liver Steatosis in MASLD/MASH Patients · NA · recruiting
- NCT06989723 — Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes · Phase 4 · recruiting
- NCT06203548 — Monitoring Changes in Hepatic Steatosis Using Continuous Controlled Attenuation Parameter · NA · recruiting
Other Seoul National University Hospital trials
Trials by the same sponsor.
- NCT07262944 — EOI Block in Otoplasty With Rib Cartilage Graft · NA · recruiting
- NCT07464210 — Nemtabrutinib, Bortezomib, and Rituximab for WM · Phase 2 · not yet recruiting
- NCT07550803 — Effect of Intraoperative Dexamethasone on Early Postoperative Sleep Quality in Patients Undergoing Nasal Surgery · NA · not yet recruiting
- NCT07522138 — Home-based Self-exercise in Patients With Parkinson's Disease: A Feasibility Study · NA · not yet recruiting
- NCT07476651 — Scout Dose of Resin Microspheres · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05695118 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Seoul National University Hospital
- Last refreshed: 18 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05695118.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing